AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Homeobox protein MSX-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P35548

UPID:

MSX2_HUMAN

Alternative names:

Homeobox protein Hox-8

Alternative UPACC:

P35548; D3DQN1; Q53XM4; Q9UD60

Background:

Homeobox protein MSX-2, also known as Homeobox protein Hox-8, plays a pivotal role in bone development and limb-pattern formation. It functions as a transcriptional regulator, repressing ALPL promoter activity and antagonizing DLX5's stimulatory effect on ALPL expression during osteoblast differentiation. MSX-2's ability to suppress transcription driven by the osteocalcin FGF response element underscores its significance in skeletal development.

Therapeutic significance:

MSX-2 is implicated in several cranial and skeletal disorders, including Parietal foramina 1, Parietal foramina with cleidocranial dysplasia, and Craniosynostosis 2. These conditions highlight the protein's crucial role in skull and clavicle ossification. Understanding MSX-2's function could lead to innovative treatments for these developmental abnormalities, offering hope for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.